Mitsubishi UFJ Asset Management Co. Ltd. Boosts Stake in IQVIA Holdings Inc. $IQV

Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 5.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 341,807 shares of the medical research company’s stock after buying an additional 17,121 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in IQVIA were worth $64,923,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Physician Wealth Advisors Inc. grew its stake in IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 134 shares during the last quarter. Westside Investment Management Inc. lifted its holdings in shares of IQVIA by 219.6% during the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after purchasing an additional 101 shares during the period. Atlantic Union Bankshares Corp purchased a new stake in IQVIA in the third quarter valued at approximately $36,000. Root Financial Partners LLC acquired a new position in IQVIA in the 3rd quarter worth approximately $43,000. Finally, Hantz Financial Services Inc. raised its position in IQVIA by 92.0% during the 3rd quarter. Hantz Financial Services Inc. now owns 240 shares of the medical research company’s stock worth $46,000 after buying an additional 115 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on IQV. Citigroup dropped their price objective on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, February 6th. Evercore reaffirmed an “outperform” rating and set a $225.00 price target on shares of IQVIA in a research report on Thursday, February 5th. Mizuho set a $215.00 price objective on IQVIA in a report on Monday. Finally, TD Cowen raised their target price on IQVIA from $215.00 to $245.00 and gave the stock a “hold” rating in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average target price of $231.80.

IQVIA Trading Up 5.0%

IQV stock opened at $179.09 on Friday. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. The firm has a market cap of $30.39 billion, a P/E ratio of 22.79, a PEG ratio of 1.64 and a beta of 1.37. The company’s 50-day simple moving average is $212.19 and its 200-day simple moving average is $207.85.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.40 by $0.02. The company had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.